aTyr eligible to receive up to $175 million in total payments, including $8 million upfront, plus tiered sales royalties Kyorin to fund all ATYR1923 development and commercialization activities in Japan SAN DIEGO , Jan. 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.

ATYR1923 safe and well tolerated in initial 15 randomized patients with pulmonary sarcoidosis No drug-related serious adverse events observed SAN DIEGO , Dec. 12, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of

Interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients due in December 2019 Company to host conference call and webcast today, November 14 , at 5:00pm EDT SAN DIEGO , Nov. 14, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.

SAN DIEGO , Nov. 13, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Dr. Sanjay Shukla , President and Chief Executive Officer of aTyr,

Management to host conference call and webcast at 5:00 pm EST / 2:00 pm PST SAN DIEGO , Nov. 07, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

Collaboration to examine the therapeutic efficacy of anti-neuropilin-2 (NRP2) antibodies in potential new roles and indications SAN DIEGO , Oct. 22, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines

SAN DIEGO , Sept. 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will be participating in two investor conferences in

SAN DIEGO , Sept. 04, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay S. Shukla , M.D., M.S., President and Chief Executive

aTyr to report interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients in Q4 2019 Company to host conference call and webcast today, August 14 , at 5:00pm EDT SAN DIEGO , Aug. 14, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.

Company to host conference call and webcast at 5pm EDT / 2pm PDT SAN DIEGO , Aug. 07, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it